News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Hydra Biosciences, Inc. and Cubist Pharmaceuticals, Inc. (CBST) Form Collaboration to Develop Novel Ion Channel Drugs for Pain Management



10/19/2009 8:43:13 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Hydra Biosciences today announced that they have entered into an agreement with Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) for a joint collaboration to develop novel ion channel drugs. The deal focuses on Hydra’s research and development program for ion channel compounds that target the TRPA1 receptor, which is believed to have an important role in pain management.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES